DMD, an X-linked recessive disorder, is the most frequent hereditary myopathy affecting approximately 1 in 3500 boys of all races. It is caused by mutations in the gene for the myocyte structural protein dystrophin. The loss of functional dystrophin in striated muscles causes extreme myocyte fragility and damage. The skeletal muscles degenerate continuously becoming fibrotic with adipose infiltrates. Clinical symptoms first manifest in boys between 18 months and 3 years of age. Muscle wasting occurs as the disease progresses and the patients become nonambulatory between 9 to 12 years of age. Mortality results from continuous loss of skeletal muscle causing spinal deformation, breathing difficulties, and cardiomyopathies. The disease is always fatal, often in the second decade and invariably in the third decade of life. There are no cures for DMD, and the current therapeutics regimens involve steroidal anti-inflamatories to limit immune responses to muscle fiber damage and only palliative treatments. Recombinant AAV may be used to restore dystrophin expression to skeletal muscles, either using a protein replacement approach, e.g. vectors that express micro-dystrophin, or an exon-skipping approach. For either application, producing sufficient quantities of rAAV to attain meaningful endpoints in the clinically relevant canine model of DMD has been the major obstacle for clinical trials. Most of the rAAV vector we produce contain a non-structural gene expressing a modified U7 RNA that interferes with processing the primary dystrophin transcript. Using specific anti-sense elements, our collaborators determined that specific exons may be omitted from the mature mRNA. This exon-skipping approach has been validated in murine DMD models and limited trials in canine DMD models. Based on these encouraging results, studies are underway using rAAV that express reporter proteins to establish the pharmacological parameters for treating DMD. From these results, the bio-distribution, routes of administration, vector toxicity are determined. Finally, using the data obtained with reporter constructs, doses that produce phenotypic improvements in large animals DMD models can then be established.

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
National Heart, Lung, and Blood Institute
Zip Code
Li, Lina; Dimitriadis, Emilios K; Yang, Yu et al. (2013) Production and characterization of novel recombinant adeno-associated virus replicative-form genomes: a eukaryotic source of DNA for gene transfer. PLoS One 8:e69879
Airenne, Kari J; Hu, Yu-Chen; Kost, Thomas A et al. (2013) Baculovirus: an insect-derived vector for diverse gene transfer applications. Mol Ther 21:739-49
Barbash, I M; Cecchini, S; Faranesh, A Z et al. (2013) MRI roadmap-guided transendocardial delivery of exon-skipping recombinant adeno-associated virus restores dystrophin expression in a canine model of Duchenne muscular dystrophy. Gene Ther 20:274-82
Smith, Richard H; Levy, Justin R; Kotin, Robert M (2009) A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields high-titer rAAV stocks from insect cells. Mol Ther 17:1888-96
Virag, Tamas; Cecchini, Sylvain; Kotin, Robert M (2009) Producing recombinant adeno-associated virus in foster cells: overcoming production limitations using a baculovirus-insect cell expression strategy. Hum Gene Ther 20:807-17
Cecchini, Sylvain; Negrete, Alejandro; Virag, Tamas et al. (2009) Evidence of prior exposure to human bocavirus as determined by a retrospective serological study of 404 serum samples from adults in the United States. Clin Vaccine Immunol 16:597-604
Cecchini, S; Negrete, A; Kotin, R M (2008) Toward exascale production of recombinant adeno-associated virus for gene transfer applications. Gene Ther 15:823-30
Smith, Richard H; Yang, Linda; Kotin, Robert M (2008) Chromatography-based purification of adeno-associated virus. Methods Mol Biol 434:37-54
Hsu, Paul Yueh-Jen; Kotin, Robert M; Yang, Ya-Wun (2008) Glucose- and metabolically regulated hepatic insulin gene therapy for diabetes. Pharm Res 25:1460-8
Negrete, Alejandro; Kotin, Robert M (2008) Strategies for manufacturing recombinant adeno-associated virus vectors for gene therapy applications exploiting baculovirus technology. Brief Funct Genomic Proteomic 7:303-11

Showing the most recent 10 out of 11 publications